SCHEMBL6818232

SCHEMBL6818232

Brc1cccc(CN2CCOCC2)c1.[Zn]

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.68
TDP1 Q9NUW8 1/20 0.68
NCF1 P14598 1/20 0.64
CNR1 P21554 1/20 0.58
CNR2 P34972 1/20 0.58
HTT P42858 3/20 0.57
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 2/20 0.57
HPGD P15428 1/20 0.57
MBTD1 Q05BQ5 1/20 0.56
L3MBTL3 Q96JM7 1/20 0.56
NOS1 P29475 1/20 0.54
HRH3 Q9Y5N1 2/20 0.51
CYP2A13 Q16696 1/20 0.50
FAAH O00519 1/20 0.49
NPC1 O15118 1/20 0.49
TP53 P04637 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL578335 0.98 SMN1; SMN2 (0.70) SMN1; SMN2TDP1NCF1CNR1CNR2
SCHEMBL17160816 0.97 SMN1; SMN2 (0.68) SMN1; SMN2TDP1NCF1CNR1CNR2
SCHEMBL11196105 0.86 NCF1 (0.83) SMN1; SMN2NCF1HTTKDM4EALDH1A1
SCHEMBL6818314 0.84 SMN1; SMN2 (0.93) SMN1; SMN2TDP1HTTKDM4EALDH1A1
SCHEMBL9025487 0.82 SMN1; SMN2 (0.96) SMN1; SMN2TDP1HTTKDM4EALDH1A1
SCHEMBL5256343 0.82 SIGMAR1 (0.58) SMN1; SMN2TDP1NCF1HTTALDH1A1
SCHEMBL3641561 0.81 SMN1; SMN2 (1.00) SMN1; SMN2TDP1HTTKDM4EALDH1A1
SCHEMBL1651281 0.80 SIGMAR1 (0.67) SMN1; SMN2TDP1HTTKDM4E
SCHEMBL29197757 0.79 SMN1; SMN2 (0.72) SMN1; SMN2TDP1HTTKDM4EALDH1A1
SCHEMBL6813604 0.79 HRH3 (0.69) SMN1; SMN2HTTKDM4EALDH1A1NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224364-A1 Organo-zinc compounds RIEKE METALS, INC. 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224364-A1 Organo-zinc compounds ZFX, CXXC5, CXXC4 SMN1; SMN2 3620/4885TDP1 3516/4885NCF1 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.